Inovio's Electroporation Patent Estate Expanded with the Allowance of Claims in Europe.

SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO) announced today the grant of an additional patent, from the European Patent Office (EPO), further expanding its electroporation technology platform. This patent (EP1023107) enhances the company's intellectual property portfolio for electroporation in Europe with claims related to the delivery of DNA-based therapeutics into muscle, the preferred tissue for extended production of antigens and other bioactive agents integral to gene therapy and DNA vaccination. The patent includes claims covering the most desirable pulsing and agent delivery conditions using electroporation.

Inovio has created a worldwide patent estate around the medical use of electroporation to deliver genes and drugs to a variety of tissues. Toward this end, Inovio acquired key DNA delivery patents with the acquisition of Inovio AS in 2005 and exclusive rights to several different patent portfolios from Sphergen and RMR in 2006. Combined with the company's own patents, Inovio believes it is the partner of choice to enable electroporation-based delivery of genes, drugs and other macromolecules for vaccination, immunotherapy and gene therapy as well as applications such as tumor ablation.

"This patent provides even more strength to our expansive patent estate involving electroporation as a means of delivering therapeutic substances," said Avtar Dhillon, CEO of Inovio. "We have assembled a preeminent patent position in the electroporation of DNA and are able to provide our partners with the optimal conditions for clinical utility and tolerability. Inovio has its CE mark and has accumulated extensive human clinical experience with electroporation, including 9 clinical trials currently underway, four involving electroporation-based delivery of therapeutic DNA."

About Inovio Biomedical Corporation

Inovio Biomedical Corporation is a late stage biomedical company focused on commercializing its proprietary Selective Electrochemical Tumor Ablation (SECTA) therapy. SECTA is designed to target a significant unmet clinical need: a local treatment for solid tumors, with selective killing of cancer cells while preserving surrounding healthy tissue. Inovio is moving its lead product, the MedPulser(R), through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal study for head and neck cancer, and Phase I trials for pancreatic and breast cancer. Merck, Vical, University of Southampton, and H. Lee Moffitt Cancer Center are using Inovio's gene delivery technology in clinical studies of novel DNA therapeutics delivered using electroporation. Inovio is a leader in developing human therapeutic applications of electroporation, with the industry's most extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2005, our Form 10-Q for the six months ended June 30, 2006, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.